In 2025, AstraZeneca conducted an environmental assessment and disclosed corporate waste management data in accordance with recognized sustainability reporting standards.The company provided a breakdown of its waste by type (hazardous vs non-hazardous) and treatment method (recovery vs disposal), enabling greater transparency into its waste handling and environmental practices.
| Metric (tonnes) | 2025 | 2024 | 2023 | 2022-2019 |
|---|---|---|---|---|
Total Waste Generated | 23,409a | 26,285a | 26,213a | |
Total Waste Recovered | 9,587a | 10,659a | 10,941a | |
Total Hazardous Waste Generated | 8,388a | 9,728a | 9,661a | |
Non-Hazardous Waste Disposed | N/A | N/A | N/A |
You are welcome to quote or reference individual data points from this page, provided you include the following attribution with a visible, clickable link to this page: "Source: Tracenable, the global reference for ESG data"
Bulk collection, scraping, resale, or redistribution of data across multiple company profiles is not permitted without our prior written permission. For more information, see our General Terms and Conditions.
Every figure on this dashboard has a transparent audit trail. With Tracenable, each data point is traceable back to its original source, viewable directly inside our platform.
In 2025, AstraZeneca generated a total of 23,409 metric tonnes of waste.a
Of this amount, 35.83% of AstraZeneca's total waste generated of was classified as hazardous waste, characterized by properties such as toxicity, flammability, corrosiveness, or reactivity that may pose risks to human health, ecosystems, or the environment.64.17% was identified as non-hazardous waste, generally considered less harmful and subject to lighter regulatory controls.a
Since 2023, AstraZeneca's total waste generation decreased by 10.7%, with an additional 10.94% decline in 2025, suggesting a consistent and deliberate effort to minimize waste generation at the source.a
Over the same period, AstraZeneca reduced the hazardousness of its waste by 2.78%, with a further 3.18% decline in 2025, suggesting a sustained and meaningful shift toward safer waste profiles and lower environmental impact.a
Overall, AstraZeneca has made consistent and substantial progress in reducing both the quantity and the danger of its waste, highlighting a strong, well-executed waste strategy focused on minimizing environmental impact.a